NASDAQ : AMPH

Amphastar Pharmaceuticals, Inc.

$19.745 USD

-$0.12 (-0.58%)

Volume
331.5K
Average Volume
614.76K
Market Capitalization
$870.61M
P/E Ratio
11.55
Dividend Yield
0.00%
Price Target
$20.50
Year High
$31.26
Year Low
$16.65
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$3.85
Source Headline
New Strong Sell Stocks for June 23rd

ARR, AMTB and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on June 23rd, 2026.

zacks.com - 2026-06-23 06:16:05

Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth

Amphastar Pharmaceuticals NASDAQ: AMPH is positioning itself for a broader shift from complex generics toward proprietary medicines and biosimilars, Chief Financial Officer and Executive Vice President of Finance Bill Peters told investors at the East Coast IDEAS Conference.

marketbeat.com - 2026-06-10 19:09:32

Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) or certain of its executive officers violated federal securities laws. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

globenewswire.com - 2026-06-08 08:19:00

Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag

Amphastar Pharmaceuticals NASDAQ: AMPH executives told investors at the Jefferies Healthcare Conference that the company is maintaining expectations for mid- to high-single-digit revenue growth in 2026, supported by a new generic launch, Primatene Mist growth and selected API sales from its China business.

marketbeat.com - 2026-06-04 00:02:26

Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be presenting at the 2026 Jefferies Healthcare Conference on Wednesday, June 3, 2026, at 4:55 p.m. ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com.

accessnewswire.com - 2026-05-27 06:00:00

Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook

Amphastar Pharmaceuticals NASDAQ: AMPH executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to remarks at the BofA Annual Healthcare Conference.

marketbeat.com - 2026-05-14 02:06:01

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-13 20:50:46

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-08 06:41:16

Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com - 2026-05-07 21:01:10

Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.7 per share. This compares to earnings of $0.74 per share a year ago.

zacks.com - 2026-05-07 18:55:25

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

Net revenues of $171.2 million for the three months ended March 31, 2026 GAAP net income of $6.4 million, or $0.14 per share, for the first quarter Adjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended March 31, 2026.

accessnewswire.com - 2026-05-07 16:05:00

Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the 2026 Bank of America Health Care Conference on Wednesday, May 13, 2026, at 3:00 pm PT. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com.

accessnewswire.com - 2026-05-06 06:00:00

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026

RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that the Company will release results for its first quarter of 2026, ended March 31, 2026, after the market closes on Thursday, May 7, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

accessnewswire.com - 2026-04-30 06:00:00

AMPH vs. RDY: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Generic Drugs sector have probably already heard of Amphastar Pharmaceuticals (AMPH) and Doctor Reddy's (RDY). But which of these two companies is the best option for those looking for undervalued stocks?

zacks.com - 2026-04-29 12:41:18

Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?

Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-29 11:01:44

Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

zacks.com - 2026-04-29 10:42:39

Get AMPH Insider Trade Alerts

AMPH Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$20.50

4 analysts

Last Year

$22.40

5 analysts

All Time

$35.11

9 analysts

AMPH Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-06-29 B of A Securities Downgrade Neutral Underperform
2026-06-03 Barclays Maintain Equal Weight Equal Weight
2026-05-14 Wells Fargo Downgrade Overweight Equal Weight
2026-05-11 Piper Sandler Maintain Neutral Neutral
2026-05-08 Needham Downgrade Buy Hold
2026-04-21 Jefferies Downgrade Buy Hold
2026-04-08 Barclays Maintain Equal Weight Equal Weight
2026-02-27 Needham Maintain Buy Buy
2026-02-27 Wells Fargo Maintain Overweight Overweight
2025-11-07 Needham Maintain Buy Buy
2025-10-22 Needham Maintain Buy Buy
2025-08-26 B of A Securities Maintain Neutral Neutral
2025-08-12 Needham Upgrade Hold Buy
2025-08-08 Piper Sandler Maintain Neutral Neutral
2025-05-12 JP Morgan Downgrade Overweight Neutral
2025-05-08 Wells Fargo Maintain Overweight Overweight
2025-04-10 Needham Maintain Hold Hold
2025-03-21 Piper Sandler Maintain Neutral Neutral
2025-02-04 Piper Sandler Downgrade Overweight Neutral
2024-08-08 Piper Sandler Maintain Overweight Overweight
2024-06-27 Piper Sandler Maintain Overweight Overweight
2023-05-17 Wells Fargo Maintain Equal Weight Equal Weight
2022-10-25 Piper Sandler Maintain Overweight Overweight
2022-07-29 Capital One Maintain Overweight Overweight
2022-03-15 Wells Fargo Maintain Equal Weight Equal Weight
2022-03-11 Piper Sandler Maintain Overweight Overweight
2022-01-07 Piper Sandler Upgrade Neutral Overweight
2021-03-17 Wells Fargo Maintain Equal Weight Equal Weight
2021-01-08 Wells Fargo Downgrade Overweight Equal Weight
2020-10-05 Northland Capital Markets Upgrade Market Perform Outperform
2020-07-09 Northland Capital Markets Downgrade Outperform Market Perform
2020-05-11 BMO Capital Maintain Market Perform Market Perform
2019-03-13 Needham Downgrade Buy Hold
2018-03-13 BMO Capital Maintain Market Perform Market Perform
2017-11-10 BMO Capital Maintain Market Perform Market Perform
2017-11-09 Raymond James Downgrade Outperform Market Perform
2017-03-14 Raymond James Downgrade Strong Buy Outperform
2016-08-09 Jefferies Maintain Buy Buy
2016-06-29 BMO Capital Maintain Market Perform Perform
2016-02-19 Wells Fargo Maintain Outperform Outperform
2016-01-19 Jefferies Maintain Buy Buy
2015-11-13 Jefferies Maintain Buy Buy
2015-06-03 Raymond James Downgrade Strong Buy Buy
2015-03-25 Jefferies Maintain Buy Buy
2014-08-13 Jefferies Maintain Buy Buy
2014-07-21 Jefferies Maintain Buy Buy
2014-07-21 Needham Maintain Buy Buy
2014-07-21 PiperJaffray Maintain Overweight Overweight
2014-07-21 BMO Capital Maintain Outperform Outperform